Secura Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Secura Bio, Inc.
The oncologic drugs advisory committee’s upcoming reviews are moving beyond the PD-1/PDL-1 inhibitor class – and to a very different type of sponsor.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.
Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals...
- Generic Drugs